PharmPK Discussion - PK Profile of cathepsin K

PharmPK Discussion List Archive Index page

On 18 Oct 2000 at 10:53:58, Jehangir Khan (jkhan.-a-.synphar.com) sent the message


Dear All,

         I am trying to construct a profile objectives of a lead compound

for Cathepsin K inhibitor to be developed as a potential drug for
osteoporosis. I have done this exercise in the past in the infectious
disease area setting up criteria for choosing a lead compound from
discovery hits based on its pharmacokinetic profile in early
pharmacokinetic studies in rodent . But as we all know the site of
inhibiting the extracellular enzyme cathepsin K is in the osteoclast,
the pharmacokinetic parameter criteria have to be set appropriately to
choose the right compound for development to get a successful clinical
outcome. Any comments or reference to set these PK criteria would be
appreciated.

Jehangir K. Khan, M.Pharm
Biopharmaceutics & Pharmacokinetics
NAEJA Pharmaceutical Inc.
Edmonton, AB, Canada

Back to the Top

Want to post a follow-up message on this topic? If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "PK Profile of cathepsin K" as the subject

PharmPK Discussion List Archive Index page